EOM 1352: Fri 7 June 2024, 11:36

Current Edition

ramusmedical
Europe

The University of Debrecen brings Hungarian patients in to Clinerion’s Patient Network Explorer.

Clinerion expands into Hungary by adding the University of Debrecen to its international patient network. The university offers clinical trial study sites with exper...
Continue Reading →
Europe

Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank

Proceeds strengthen balance sheet and cash visibilityPayment triggered by the achievement of 2 key company milestones:Determination of the recommended dose at 22% of...
Continue Reading →
news

Nightstar acquisition will catapult Biogen in global ophthalmology market, says GlobalData

Following the news on 4th March 2019 that US-based biotechnology company, Biogen, has agreed to acquire London-based clinical-stage gene therapy company, Nightstar T...
Continue Reading →
Asia Pacific

WuXi STA and Ark Biosciences Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Ark Biosciences, a global biotech company focusing on innovative drug discovery and deve...
Continue Reading →
Europe

Diabetes: telemedicine and data science can improve patient care

(Vienna, 25 February 2019) The care of patients with chronic diseases could be improved by regular telemonitoring. This is the finding of a recent study conducted by...
Continue Reading →
Europe

CRF Bracket Grows More in First Quarter Together than Either Company Achieved Alone in 2018

Pharma industry validates shared vision, strong neuroscience interest, and greater operational scale as robust results illustrate greater than 20% increase in new cl...
Continue Reading →
Europe

AstraZeneca’s PARP drug succeeds in pancreatic cancer study

AstraZeneca's targeted cancer therapy Lynparza met the primary endpoint of a Phase 3 study testing the drug as a first-line maintenance treatment for a subset of pan...
Continue Reading →
news

Novartis moves forward on CV drug, paying $150M to Ionis, Akcea

Novartis said Monday it will exercise a licensing option on an experimental heart drug, paying $75 million to both Ionis Pharmaceuticals and Akcea Therapeutics as it...
Continue Reading →
Europe

Brilinta’s Phase III THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significa...
Continue Reading →
Europe

New treatment offers potentially promising results for the possibility of slowing, stopping, or even reversing Parkinson’s disease

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged...
Continue Reading →
Quotient